Pfizer, Merck KGaA skin cancer drug gets EMA nod for approval

(Reuters) - European regulators on Friday recommended approving Pfizer Inc and Merck KGaA's immuno-oncology drug Bavencio to treat a rare type of skin cancer called Merkel cell carcinoma.